[Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma].

[1]  A. Bohle.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer , 2009 .

[2]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[3]  L. Martínez-Piñeiro,et al.  Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. , 2008, European urology.

[4]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[5]  Ruifa Han,et al.  Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. , 2006, Urology.

[6]  Liang Cheng,et al.  Bladder cancer: epidemiology, staging and grading, and diagnosis. , 2005, Urology.

[7]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[8]  P. Sogani,et al.  Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? , 2001, The Journal of urology.

[9]  J. Patard,et al.  Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. , 2001, Urology.

[10]  P. Schellhammer,et al.  Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. , 2000, The Journal of urology.

[11]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[12]  L. Kiemeney,et al.  Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. , 1998, Urology.

[13]  L. True,et al.  The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder , 1990, Cancer.

[14]  H. Wallerand,et al.  [Recommendations Onco-Urology 2010: Urothelial tumors]. , 2010, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[15]  M. Rouprêt,et al.  [T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU)]. , 2010, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[16]  D. Margel,et al.  Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. , 2007, Urology.

[17]  H. Wallerand,et al.  The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. , 2001, The Journal of urology.